Inventor · disambiguated record
Illana Gozes
Also filed as: GOZES ILLANA
29 granted patents·11 pending applications·542 citations·filing 1989–2022
97Inventor score
Top patents by PatentIndex Score
40 records- 0193US7452867B2Use of ADNF polypeptides for treating peripheral neurotoxicityUNIV RAMOT·Filed 2006·Granted Nov 18, 2008·27 cites·24 claims
- 0288US8017578B2Orally active peptides that prevent cell damage and deathUS HEALTH·Filed 2008·Granted Sep 13, 2011·6 cites·6 claims
- 0387US7264947B2Activity dependent neurotrophic factor III (ADNF III)US HEALTH·Filed 2003·Granted Sep 4, 2007·26 cites·12 claims
- 0486US8324166B2Neuroprotection using NAP-like and SAL-like peptide mimeticsGOZES ILLANA·Filed 2010·Granted Dec 4, 2012·10 cites·10 claims
- 0586US8067369B2Protection of the retina against laser injury by NAP and related peptidesGOZES ILLANA·Filed 2006·Granted Nov 29, 2011·4 cites·23 claims
- 0684US7384908B1Orally active peptides that prevent cell damage and deathUS HEALTH·Filed 2000·Granted Jun 10, 2008·17 cites·12 claims
- 0782US7863247B1Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptidesUNIV RAMOT·Filed 2000·Granted Jan 4, 2011·17 cites·21 claims
- 0881US7427598B2Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memoryUS HEALTH·Filed 2001·Granted Sep 23, 2008·15 cites·22 claims
- 0981US6613740B1Activity dependent neurotrophic factor III (ADNF III)UNIV RAMOT·Filed 1998·Granted Sep 2, 2003·49 cites·16 claims
- 1081US5972883AMethod for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereofYEDA RES & DEV·Filed 1995·Granted Oct 26, 1999·37 cites·9 claims
- 1180US8143221B2Use of ADNF polypeptides for treating peripheral neurotoxicityGOZES ILLANA·Filed 2008·Granted Mar 27, 2012·4 cites·21 claims
- 1280US5147855AConjugates of vip and active fragments thereof with hydrophobic moieties and topical compositions for male impotenceYEDA RES & DEV·Filed 1989·Granted Sep 15, 1992·36 cites·8 claims
- 1379US10118943B2Compounds and methods for inhibiting cell deathUNIV RAMOT·Filed 2013·Granted Nov 6, 2018·4 cites·12 claims
- 1479US6239107B1Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)YEDA RES & DEV·Filed 1997·Granted May 29, 2001·47 cites·24 claims
- 1578US7427590B2Neurothrophic components of the ADNF I complexUS HEALTH·Filed 2002·Granted Sep 23, 2008·15 cites·16 claims
- 1676US5767240AActivity-dependent neurotrophic factorUS HEALTH·Filed 1992·Granted Jun 16, 1998·33 cites·10 claims
- 1775US8377875B2Therapeutics based on tau/microtubule dynamicsUNIV RAMOT·Filed 2008·Granted Feb 19, 2013·4 cites·9 claims
- 1875US6630124B1Combination therapy with VIP antagonistUNIV RAMOT·Filed 1999·Granted Oct 7, 2003·55 cites·47 claims
- 1974US5565424ASuperactive VIP antagonistsUNIV RAMOT·Filed 1994·Granted Oct 15, 1996·29 cites·26 claims
- 2073US8586548B2NAP alpha-aminoisobutyric acid analog with neuroprotective activityGOZES ILLANA·Filed 2010·Granted Nov 19, 2013·2 cites·8 claims
- 2171US9518994B2Method for diagnosing and monitoring schizophrenia and tauopathiesGOZES ILLANA·Filed 2011·Granted Dec 13, 2016·3 cites·18 claims
- 2271US5217953AVasoactive intestinal peptide antagonistUS HEALTH·Filed 1990·Granted Jun 8, 1993·30 cites·3 claims
- 2369US8618043B2Use of ADNF polypeptides for treating anxiety and depressionGOZES ILLANA·Filed 2011·Granted Dec 31, 2013·2 cites·13 claims
- 2469US7960334B2Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophreniaUNIV RAMOT·Filed 2004·Granted Jun 14, 2011·6 cites·12 claims
- 2567US6933277B2Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptidesUNIV RAMOT·Filed 1999·Granted Aug 23, 2005·28 cites·16 claims
- 2666US6649411B2Methods of inhibiting cancer cells with ADNF III antisense oligonucleotidesUS HEALTH·Filed 1999·Granted Nov 18, 2003·22 cites·13 claims
- 2761US2025032581A1Compositions and articles comprising an adnf polypeptideUNIV RAMOT·Filed 2022·Application pending·0 cites
- 2859US2025032580A1Use of adnf polypeptides in therapyUNIV RAMOT·Filed 2022·Application pending·0 cites
- 2959US2023098833A1Deepdrug: an expert-led directed graph neural networking drug-repurposing framework for identification of a lead combination of drugs protecting against alzheimer's disease and related disordersUNIV HONG KONG·Filed 2022·Application pending·0 cites
- 3058US2009124543A1Activity dependent neurotrophic factor iii (adnf iii)US GOV HEALTH & HUMAN SERV·Filed 2007·Application pending·0 cites
- 3157US10912819B2Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseasesUNIV RAMOT·Filed 2017·Granted Feb 9, 2021·0 cites·13 claims
- 3257US10822375B2Method for identifying a modulator of cell survival or plasticityUNIV RAMOT·Filed 2018·Granted Nov 3, 2020·0 cites·7 claims
- 3354US5998368ADerivatives of structurally modified VIP and pharmaceutical compositions containing themYEDA RES & DEV·Filed 1997·Granted Dec 7, 1999·14 cites·19 claims
- 3453US2025312408A1Nap for sex-specific treatment of diseasesUNIV RAMOT·Filed 2022·Application pending·0 cites
- 3552US2022340955A1Methods for diagnosing and treatment monitoring of adnp-deficient patientsUNIV RAMOT·Filed 2020·Application pending·0 cites
- 3651US2013123186A1Neuroprotection using nap-like and sal-like peptide mimeticsGOZES ILLANA·Filed 2012·Application pending·0 cites
- 3747US2005075284A1Pharmaceutical compositions comprising vip-related peptides for the treatment of sexual disordersFiled 2001·Application pending·0 cites
- 3845US2004235747A1Methods of treating and/or preventing autoimmune diseasesUNIV RAMOT·Filed 2003·Application pending·0 cites
- 3939US2012010148A1Combination therapies using napGOZES ILLANA·Filed 2011·Application pending·0 cites
- 4032US2013053320A1Treatment of anemia by adnp and adnf polypeptidesGOZES ILLANA·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Illana Gozes files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →